Concepedia

Sarah M. Larson

SM

Statistics

Publications

41

Citations

2.6K

H-Index

23

Active since

1977

Affiliations

University of California, Los Angeles(Current)

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Washington University in St. Louis

Moffitt Cancer Center

Sarah M. Larson is an author at University of California, Los Angeles specializing in medicine, oncology, and immunology.

ORCID

Top concepts

Publications per year

1977–2025

41

Publications

41

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Kehinde Adekola et al. · Journal of the National Comprehensive Cancer Network · 2020 · 273 citations

, , +10

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold et al. · The Lancet Haematology · 2019 · 249 citations · Full text

, , +6

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol et al. · The Lancet Haematology · 2019 · 237 citations · Full text

, , +7

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

Natalie S. Callander, Muhamed Baljević, Kehinde Adekola et al. · Journal of the National Comprehensive Cancer Network · 2022 · 200 citations

, , +11

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma

Todd A. Fehniger, Sarah M. Larson, Kathryn Trinkaus et al. · Blood · 2011 · 192 citations · Full text

1–5 of 41